(Reuters) -Amylyx Pharmaceuticals Inc said on Friday it has set the list price of its newly approved drug to slow the progression of amyotrophic lateral sclerosis (ALS) at about $158,000
Amylyx says doctors will be able to prescribe Relyvrio immediately. The drugmaker anticipates prescriptions will be filled and shipped from specialty pharmacies within the next four to six weeks.
(Reuters) - Amylyx Pharmaceuticals Inc said on Friday it has set the price of its drug to slow the progression of ALS - amyotrophic lateral sclerosis .
Amylyx Pharmaceuticals Inc
said on Thursday the U.S. Food and Drug Administration approved
its drug for slowing progression of ALS, or amyotrophic lateral
sclerosis, and potentially delaying death,. | September 30, 2022